|
CN111398489A
|
|
High performance liquid chromatography analysis method of aprepitant related substances
|
|
CN111494326A
|
|
Apixaban tablet and preparation method thereof
|
|
CN111272608A
|
|
Content determination method of stable ionic iodine contrast agent
|
|
WO2020156437A1
|
|
Akt inhibitor
|
|
CN111067960A
|
|
Preparation method of traditional Chinese medicine composition for treating prostate diseases
|
|
CN110981863A
|
|
Preparation method of β -glucoside compound with high stereoselectivity
|
|
CN111087421A
|
|
Preparation method of phosphamide compound for chiral drug synthesis
|
|
CN110981910A
|
|
Novel crystal form without hygroscopicity and low variability for treating hepatitis C
|
|
CN111072742A
|
|
Novel crystal form of medicine for treating hepatitis C and composition thereof
|
|
WO2020114418A1
|
|
Anticoagulant pentasaccharide compound, composition, and preparation method and medical use thereof
|
|
CN112279401A
|
|
Method for treating lanthanum ions in industrial wastewater
|
|
CN112010913A
|
|
Preparation method of 4-deoxy daunorubicin
|
|
CN110146639A
|
|
A kind of analysis method of the novel nucleoside acids reverse transcriptase inhibitor in relation to substance
|
|
CN111943904A
|
|
Method for refining key intermediate of neurokinin 1 receptor antagonist
|
|
CN109985040A
|
|
A kind of injection Parecoxib Sodium Pharmaceutical composition and preparation method thereof for preemptive analgesia
|
|
CN109956901A
|
|
The preparation method of compound of isobioquin group
|
|
CN109674762A
|
|
A kind of composition capsule of dutasteride and hair growth
|
|
CN111351869A
|
|
Analysis method for determining substances related to lubiprostone test sample
|
|
CN111351867A
|
|
Analysis method for determining substances related to lubiprostone test sample
|
|
CN111138363A
|
|
Tolvaptan impurity compound and preparation method and application thereof
|
